Afatinib (BIBW2992)阿法替尼
- 品牌：TargetMol
- 型号：439081-18-2
- 产地：USA
- 供应商：南京莱富赛生物科技有限公司
- 供应商报价：￥759 - 3535
- 标签：Afatinib (BIBW2992)阿法替尼、Afatinib (BIBW2992)阿法替尼价格、Afatinib (BIBW2992)阿法替尼厂家、Afatinib (BIBW2992)、、南京莱富赛生物科技有限公司
产品库
| 规格： | 5mg | 产品价格： | ￥759.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥1313.0 |
| 规格： | 50mg | 产品价格： | ￥3535.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥920.0 |
ID：T2303
PURITY：97%+
Formula：C24H25ClFN5O3
MolWt：485.94
Appearance：白色粉末
Solubility：G4Soluble in DMSO
Bioactivity：Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.
Status：
Pathways：Tyrosine Kinase/Adaptors
Target：EGFR inhibitor
Receptor：EGFR
